Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Jun;20(6):844-7.
doi: 10.5588/ijtld.15.0882.

Isoniazid hair concentrations in children with tuberculosis: a proof of concept study

V Mave  1 , A Chandanwale  2 , A Kinikar  2 , S Khadse  2 , A Kagal  2 , N Gupte  1 , N Suryavanshi  2 , S Nimkar  2 , H Koli  2 , S Khwaja  2 , R Bharadwaj  2 , S Joshi  2 , H Horng  3 , L Z Benet  3 , G Ramachandran  4 , K E Dooley  5 , A Gupta  1 , M Gandhi  3
Affiliations

Isoniazid hair concentrations in children with tuberculosis: a proof of concept study

V Mave et al. Int J Tuberc Lung Dis. 2016 Jun.

Abstract

Assessing treatment adherence and quantifying exposure to anti-tuberculosis drugs among children is challenging. We undertook a 'proof of concept' study to assess the drug concentrations of isoniazid (INH) in hair as a therapeutic drug monitoring tool. Children aged <12 years initiated on a thrice-weekly treatment regimen including INH (10 mg/kg) for newly diagnosed tuberculosis were enrolled. INH concentrations in hair were measured using liquid chromatography-tandem mass spectrometry at 1, 2, 4 and 6 months after initiating anti-tuberculosis treatment. We found that INH hair concentrations in all children on thrice-weekly INH were detectable and displayed variability across a dynamic range.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Hair isoniazid concentrations among children at 1, 2, 4 and 6 months on tuberculosis therapy (n=38)
1a. Hair isoniazid concentrations by months on tuberculosis therapy. Months on tuberculosis therapy is shown in Y-axis. Dots in the figure represent outlier values; 1b. Sphagetti plot illustrating intra-individual variability of hair isoniazid concentrations over 6 months on tuberculosis therapy. Each line indicates the individual hair isoniazid concentrations at month 1, 2, 4 and 6 on tuberculosis therapy.
Figure 1
Figure 1. Hair isoniazid concentrations among children at 1, 2, 4 and 6 months on tuberculosis therapy (n=38)
1a. Hair isoniazid concentrations by months on tuberculosis therapy. Months on tuberculosis therapy is shown in Y-axis. Dots in the figure represent outlier values; 1b. Sphagetti plot illustrating intra-individual variability of hair isoniazid concentrations over 6 months on tuberculosis therapy. Each line indicates the individual hair isoniazid concentrations at month 1, 2, 4 and 6 on tuberculosis therapy.
See this image and copyright information in PMC

References

    1. World Health Organization. Document WHO/HTM/TB/2015 22. Geneva: World Health Organization; 2015. [Accessed 25th November 2015]. Global tuberculosis report 2015. www.who.int/tb/publications/global_report/en/
    1. Peloquin CA. Therapeutic drug monitoring in the treatment of tuberculosis. Drugs. 2002;62(15):2169–83. 2002. - PubMed
    1. Pasipanodya JG, Srivastava S, Gumbo T. Meta-analysis of clinical studies supports the pharmacokinetic variability hypothesis for acquired drug resistance and failure of antituberculosis therapy. Clin Infect Dis. 2012;55(2):169–177. - PMC - PubMed
    1. Podsadecki TJ, Vrijens BC, Tousset EP, Rode RA, Hanna GJ. “White coat compliance” limits the reliability of therapeutic drug monitoring in HIV-1-infected patients. HIV Clin Trials. 2008;9(4):238–246. - PubMed
    1. Garcia-Martin E. Interethnic and intraethnic variability of NAT2 single nucleotide polymorphisms. Current Drug Metabolism. 2008;9:487–97. - PubMed

Publication types